Liv Pure Peptide Product: Klow

Liv Pure Peptides Klow (GHK-cu 50mg / BPC-157 10mg / TB4 10mg / KPV 10mg) Categories: Anti Aging, Recovery & Healing, Blends $175.00 (BLEND) GHK-Cu (Copper Tripeptide-1) CAS# 49557-75-7 Formula: C14H24CuN6O4 Molecular Weight: 403.86 g/mol Amount: 50mg

(BLEND) BPC-157 CAS# 137525-51-0 Formula: C62H98N16O22 Molecular Weight: 1419.53 g/mol Amount: 10mg

(BLEND) Thymosin Beta-4 (TB4) CAS# 77591-33-4 Formula: C212H350N56O78S Molecular Weight: 4963.49 g/mol Amount: 10mg

(BLEND) KPV (Lys–Pro–Val) CAS# N/A Formula: C16H30N4O4 Molecular Weight: 342.44 g/mol Amount: 10mg

KLOW is an 80 mg multi-peptide blend formulated by Liv Pure for complementary pathway interrogation. Useful for pilot screens, receptor panels, and exploratory method development across assays.

Sizes

At Liv Pure Peptides, innovation meets purity. Our advanced research and rigorous quality standards deliver breakthrough peptide solutions for better health and science.

Shop Products

Products

Pages

Legal

Newsletter Signup

YOU MUST BE OVER 21 YEARS OLD TO USE THIS WEBSITE.

All products provided by Liv Pure are intended solely for in‑vitro laboratory research purposes. These materials are expressly forbidden for any form of human or animal use, ingestion, or administration, and all products are sold strictly for research, laboratory, or analytical purposes – not for human consumption.

The products offered on this platform are not formulated, designed, or intended to diagnose, cure, mitigate, treat, or prevent any diseases or medical conditions. Additionally, these statements have not been evaluated by the Food and Drug Administration, and our products are not intended to diagnose, treat, cure, or prevent any disease.

All products are for Research and Development use only and are not for human consumption.

Liv Pure is a chemical supplier; LIV Pure Peptides is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor is it an outsourcing facility as defined under Section 503B of the Act.